117 related articles for article (PubMed ID: 37909951)
1. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases.
Inoue K; Mizuma M; Motoi F; Kokumai T; Sato H; Kusaka A; Aoki S; Iseki M; Douchi D; Miura T; Maeda S; Ishida M; Ohtsuka H; Nakagawa K; Kamei T; Unno M
Anticancer Res; 2023 Nov; 43(11):5223-5234. PubMed ID: 37909951
[TBL] [Abstract][Full Text] [Related]
2. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
3. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
4. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
5. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
[TBL] [Abstract][Full Text] [Related]
6. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma - A case-control study.
Shao Y; Feng J; Hu Z; Wu J; Zhang M; Shen Y; Zheng S
Ann Med Surg (Lond); 2021 Feb; 62():490-494. PubMed ID: 33680449
[TBL] [Abstract][Full Text] [Related]
10. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
Ferrone CR; Finkelstein DM; Thayer SP; Muzikansky A; Fernandez-delCastillo C; Warshaw AL
J Clin Oncol; 2006 Jun; 24(18):2897-902. PubMed ID: 16782929
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
12. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.
Abdel-Misih SR; Hatzaras I; Schmidt C; Saab TB; Klemanski D; Muscarella P; Melvin WS; Ellison EC; Bloomston M
Ann Surg Oncol; 2011 Apr; 18(4):1116-21. PubMed ID: 21042945
[TBL] [Abstract][Full Text] [Related]
13. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
14. Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection.
Chen H; Li F; Zou S; Xie J; Zhang J; Deng X; Chen H; Shen B
World J Surg Oncol; 2021 Jun; 19(1):166. PubMed ID: 34107980
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
[TBL] [Abstract][Full Text] [Related]
16. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
[TBL] [Abstract][Full Text] [Related]
17. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
18. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum CA19-9 predicts postoperative pancreatic fistula in PDAC patients: retrospective analysis at a single institution.
Sugita H; Okabe H; Ogawa D; Hirao H; Kuroda D; Taki K; Tomiyasu S; Hirota M
BMC Surg; 2022 Oct; 22(1):367. PubMed ID: 36307795
[TBL] [Abstract][Full Text] [Related]
20. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
